Immatics Biotechnologies GmbH

Quick facts

Phase 3 pipeline

• IMA901 · Oncology
  IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

Phase 2 pipeline

• Endoxana, IMA901, Leukine
• IMA901 and Leukine

Phase 1 pipeline

• APVAC1 vaccine plus Poly-ICLC and GM-CSF · Oncology
  APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.
• APVAC2 vaccine plus Poly-ICLC and GM-CSF · Oncology
  APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells.
• Endoxana, Leukine, IMA910
• Endoxana, Leukine, IMA910, Aldara

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Immatics Biotechnologies GmbH portfolio CI brief
• Immatics Biotechnologies GmbH pipeline updates RSS